Six-Year Study Will Compare Bayer’s Essure With Tubal Ligation
Executive Summary
US FDA has accepted a post-approval study plan by Bayer HealthCare for its Essure permanent sterilization device, which is under intense scrutiny in response to adverse events and charges of clinical trial misconduct. The protocol entails a non-randomized, six-year cohort study comparing Essure-implanted women to tubal ligation sterilization subjects.
You may also be interested in...
Bayer Halts Essure Sales In EU As US FDA Relies On Study, Patient Warnings
Bayer AG said Sept. 18 it will not renew a CE mark for its Essure permanent contraceptive coils for women in EU countries, effectively halting sales of the product outside the US. The firm says its decision was "unrelated to product safety or efficacy," and driven by its commercial strategy. Meanwhile, US FDA calls for warnings and black box labels for Essure in the US, and says a Sec. 522 post-market study it ordered Bayer to complete "will help us better understand" thousands of complaints about the device.
FDA Says Bayer's Response To Essure Investigation Satisfactory; Approves Product Label
FDA completed its investigation of a February 2015 trade complaint that charged clinical trial misconduct by Bayer HealthCare LLC for its controversial Essure permanently implanted birth control device, finding Bayer's response "satisfactory." The agency also approved amended labeling for the device.
US House Members Urge Hearings On Device Safety
A bipartisan coalition of seven members of the US House asked Energy and Commerce Committee leaders to hold hearings on medical device safety, trying to bring more attention to provisions that might strengthen safety oversight amid all the talk of accelerating medical innovation.